Oxford Biomedica plc Stock price

Equities

OXB

GB00BDFBVT43

Biotechnology & Medical Research

Delayed London S.E. 06:27:31 2024-03-28 am EDT 5-day change 1st Jan Change
197.7 GBX +0.26% Intraday chart for Oxford Biomedica plc +1.49% -10.13%
Sales 2023 * 90.32M 114M Sales 2024 * 130M 163M Capitalization 197M 248M
Net income 2023 * -89M -112M Net income 2024 * -38M -47.84M EV / Sales 2023 * 1.67 x
Net cash position 2023 * 46.24M 58.21M Net cash position 2024 * 12.81M 16.12M EV / Sales 2024 * 1.42 x
P/E ratio 2023 *
-2.17 x
P/E ratio 2024 *
-5.12 x
Employees 891
Yield 2023 *
-
Yield 2024 *
-
Free-Float 80.8%
More Fundamentals * Assessed data
Dynamic Chart
1 day-0.10%
1 week+1.64%
Current month+15.12%
1 month+14.98%
3 months-8.97%
6 months-33.33%
Current year-10.00%
More quotes
1 week
187.20
Extreme 187.2
199.80
1 month
167.00
Extreme 167
220.00
Current year
167.00
Extreme 167
220.00
1 year
164.29
Extreme 164.288
474.50
3 years
164.29
Extreme 164.288
1 678.00
5 years
164.29
Extreme 164.288
1 678.00
10 years
88.70
Extreme 88.7
1 678.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 62 23-03-26
Director of Finance/CFO 52 17-08-28
Chairman 68 20-06-23
Members of the board TitleAgeSince
Director/Board Member 61 23-04-30
Chairman 68 20-06-23
Director/Board Member 66 16-05-31
More insiders
Date Price Change Volume
24-03-28 197.7 +0.26% 3 219
24-03-27 197.2 +1.34% 213,723
24-03-26 194.6 +0.10% 416,326
24-03-25 194.4 -1.22% 225,510
24-03-22 196.8 +1.03% 208,090

Delayed Quote London S.E., March 28, 2024 at 05:10 am EDT

More quotes
Oxford Biomedica Plc is a United Kingdom-based viral vector specialist that is primarily focused on delivering therapies to patients. The Company and its subsidiaries are engaged in viral vector delivery systems, including those based on lentivirus, adeno-associated virus (AAV) and adenovirus. It provides solutions to cell and gene therapy biotechnology and biopharma companies for their process development, analytical development and manufacturing needs. The Company has built a LentiVector platform, which is focused on a lentiviral vector delivery system. Its LentiVector platform is engaged in working on programs from the pre-clinical to commercial stages across a range of therapeutic areas with global partners. The Company has manufacturing, laboratory and office space across six facilities in Oxford, United Kingdom. The Company's subsidiary, Oxford Biomedica Solutions LLC, has an AAV manufacturing facility near Boston, Massachusetts, the United States.
Calendar
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
9
Last Close Price
1.972 GBP
Average target price
4.154 GBP
Spread / Average Target
+110.64%
Consensus
  1. Stock
  2. Equities
  3. Stock Oxford Biomedica plc - London S.E.